MW Here's how much weight-loss drugs Wegovy, Zepbound and Foundayo cost - and how to pick the best GLP-1 for you
By Genna Contino
As a new weight-loss pill and high-dose injection enter the market, costs have plummeted to a fraction of their original price
GLP-1 drugs now come in injectables and pills - but figuring out how to pay for them can get complicated.
Taking GLP-1s once meant injecting a shot with a monthly price tag of $1,000. Today, patients interested in the wildly popular weight-loss drugs can choose among different types of injectables and even pills, with discounted cash prices dipping as low as $149.
The market for weight-loss medications is still expanding, too. Drugmaker Novo Nordisk (NVO) announced Tuesday that a higher dosage of its Wegovy injectable is now available in the U.S., adding another option to the marketplace just a week after the Food and Drug Administration approved Foundayo, a weight-loss pill developed by competitor Eli Lilly $(LLY)$.
Figuring out how to pay for these drugs can be complicated, and it's a key issue for consumers as healthcare costs and insurance premiums soar.
Just 19% of commercial insurance plans offered by companies with 200 or more employees covered GLP-1 drugs for weight loss in 2025, according to a health-benefits survey from KFF, a nonpartisan health-policy research, polling and news organization - and when they do, they often come with restrictions. That means many patients are forced to pay out of pocket or seek out manufacturer coupons to help ease the cost burden.
Read more: The new high dose of Wegovy costs less than Zepbound
Healthcare analysts say Novo Nordisk has made the most effort to provide affordable obesity treatment options for self-paying patients, in part because Lilly's drugs have the most market share, but price points for medications from both companies remain largely similar. As new options pop up, patients have more control over how they take the medication and how they pay for it.
"This is a very consumer-driven market. It's a lifestyle condition. Insurance coverage isn't great, and so a lot of people end up choosing to just pay out of pocket," said Divya Iyer, senior vice president and resident GLP-1 expert at prescription-savings website GoodRx $(GDRX)$. "When we think about what determines who the winner will be, it will be the brand that has the most affordable price."
Experts note that these are long-term maintenance medications. Because patients often regain weight after stopping treatment, many are expected to stay on the drugs indefinitely in order to maintain their results.
Here's a look at the different mainstream weight-loss drugs, their price points and how to pay for them.
Injectables vs. pills
The first thing patients should check is if their insurance covers GLP-1 drugs for weight loss. Those who have commercial coverage can often use a manufacturer savings card from drugmakers like Novo Nordisk or Eli Lilly to lower the out-of-pocket co-pay to as little as $25 per month.
Those who are uninsured or have plans that don't cover GLP-1s for weight loss have to look into manufacturer-direct partnerships and tiered self-pay programs to avoid the eye-popping list prices for injectables, which can top $1,000. These programs can cut those costs by up to 70% for savvy self-paying shoppers.
Read more: America has a new weight-loss drug, and it's a pill
The newer weight-loss pills are a bit cheaper, because they "are easier to produce," Iyer said. "The injections have to be stored at a lower temperature, which drives up costs."
Here's a breakdown of the most popular FDA-approved injectables and pills for weight loss.
Injectables:
-- Wegovy's auto-injector starts at $199 for two months of starter doses through specific introductory cash-pay offers, then jumps to $349 per month.
-- Lilly's Zepbound vial and syringe (single-dose vials) starts at $299 per month for the starter dose via direct-to-patient platforms like LillyDirect.
-- Zepbound's KwikPen, which is a multidose device containing a full month of treatment in a single pen, also starts at $299 per month for the starter dose.
-- Zepbound's auto-injector, a single-dose pen, has a list price of $1,060 - the most expensive option for cash-paying patients that's typically used by those with insurance plans that cover most of the cost.
-- Novo Nordisk also has a cheaper price than Lilly for its new high-dose injectable: Wegovy HD costs $399 per month, while the four highest dosages of Zepbound's competing pen are $449 per month.
Pills:
-- The Wegovy pill costs $149 to $299 per month, depending on dosage.
-- Foundayo's price ranges from $149 to $399 per month.
"Lilly's pricing for Foundayo appears similar to Wegovy pill but higher at the highest doses, which to me says that they aren't interested in getting into a price battle with Novo or compounders to win oral patients in the U.S. self-pay market," said Karen Andersen, healthcare director at Morningstar Equity Research $(MORN)$.
How to find those prices - and not get hit with surprise charges
Saving on GLP-1s requires choosing the right portal. TrumpRx, a government-operated platform launched in February that highlights some discounted medications from drugmakers, serves as a federal hub for self-paying patients, offering the lowest rates for those who buy directly from sites like LillyDirect. Platforms like GoodRx provide a vital cross-check, listing similar coupons alongside separate pharmacy discounts that can sometimes beat federal rates.
Read more: It's time to rethink how we define obesity as millions turn to GLP-1s
Some patients have opted to get weight-loss medications from direct-to-consumer platforms like Hims & Hers Health $(HIMS)$, Ro or Weight Watchers $(WW)$. Novo Nordisk even announced a Wegovy subscription program with these platforms at the end of March. But keep in mind that convenience comes at a cost - these apps have membership fees tacked on top of what users pay for a prescription.
Hims & Hers recently faced regulatory pressure and a lawsuit from Novo Nordisk for selling compounded GLP-1 drugs that are not FDA-approved. The company has since ended the dispute with Novo Nordisk and now only advertises FDA-approved products. It still "plans to offer access to compounded GLP-1s if a provider determines that a compounded product is clinically necessary," according to a company news release.
Whether they're paying just $25 using a coupon with insurance or getting a discounted self-pay price, patients should read the fine print, experts urge. Some insurance plans don't count manufacturer coupons toward a deductible, which can lead to a massive surprise bill mid-year, said KFF senior policy manager Michelle Long.
Those paying out of pocket might find that their discounts have usage caps or introductory offers. For example, Lilly's terms and conditions specify that Foundayo self-pay discounts can only be used 10 months per year. The Wegovy injectable pen is advertised at a monthly cost of $199 for specific dosages, but that jumps to $349 after two months.
"There's a lot of caveats, a lot of complexity in an already extremely complex, fragmented and nuanced healthcare system," Long said.
Read next: Half of GLP-1 users ditch their injections - and some are turning to other weight-loss methods instead
What personal-finance issues would you like to see covered in MarketWatch? We would like to hear from readers about their financial decisions and money-related questions. You can write to us at readerstories@marketwatch.com. A reporter may be in touch to learn more. MarketWatch will not attribute your answers to you by name without your permission.
-Genna Contino
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
April 09, 2026 13:37 ET (17:37 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments